Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-945-7361
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees61
OptionableNot Optionable
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
How were Translate Bio's earnings last quarter?
Translate Bio Inc (NASDAQ:TBIO) announced its earnings results on Thursday, November, 8th. The company reported ($0.97) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.93. The company earned $0.24 million during the quarter, compared to analysts' expectations of $22.50 million. View Translate Bio's Earnings History.
When is Translate Bio's next earnings date?
What price target have analysts set for TBIO?
4 equities research analysts have issued 1-year target prices for Translate Bio's stock. Their predictions range from $20.00 to $25.00. On average, they anticipate Translate Bio's share price to reach $22.75 in the next twelve months. This suggests a possible upside of 311.4% from the stock's current price. View Analyst Price Targets for Translate Bio.
What is the consensus analysts' recommendation for Translate Bio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.
Has Translate Bio been receiving favorable news coverage?
Headlines about TBIO stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Translate Bio earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Solid Biosciences (SLDB), Coherus Biosciences (CHRS), Novavax (NVAX), Vericel (VCEL), Acorda Therapeutics (ACOR), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), Cellectis (CLLS), Twist Bioscience (TWST), NanoString Technologies (NSTG), Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI), Gritstone Oncology (GRTS), Mesoblast (MESO) and Agenus (AGEN).
Who are Translate Bio's key executives?
Translate Bio's management team includes the folowing people:
- Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 49)
- Dr. Michael W. Heartlein, Chief Scientific Officer & CTO (Age 59)
- Mr. John R. Schroer CFA, CFO & Treasurer (Age 53)
- Mr. Paul D. Burgess J.D., Gen. Counsel (Age 45)
- Ms. Paula A. Cloghessy, Sr. VP of Human Resource (Age 47)
When did Translate Bio IPO?
(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.
When did Translate Bio's lock-up period expire?
Translate Bio's lock-up period expired on Tuesday, December 25th. Translate Bio had issued 9,350,000 shares in its initial public offering on June 28th. The total size of the offering was $121,550,000 based on an initial share price of $13.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.
How do I buy shares of Translate Bio?
Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Translate Bio's stock price today?
One share of TBIO stock can currently be purchased for approximately $5.53.
How big of a company is Translate Bio?
Translate Bio has a market capitalization of $249.64 million. Translate Bio employs 61 workers across the globe.
What is Translate Bio's official website?
How can I contact Translate Bio?
Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.
MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
